登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C42H84ClNO2
化学文摘社编号:
分子量:
670.57
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
assay
>99% (TLC)
form
powder
packaging
pkg of 2 × 100 mg (890898P-200mg), pkg of 1 × 25 mg (890898P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
advanced drug delivery
lipid type
cationic lipids
transfection
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]
InChI key
LDGWQMRUWMSZIU-LQDDAWAPSA-M
Application
DOTMA适合作为miRNA递送系统的结构单元并用于制备。
Biochem/physiol Actions
DOTMA是一种阳离子脂质，可用作基因治疗的非病毒载体。它对体外和体内基因转染均有作用。DOTMA可使脂质体带上正电荷，因此促成更高效的脂质体-细胞膜相互作用。
Packaging
5 mL透明玻璃密封安瓿瓶(890898P-200mg)
5 mL透明玻璃密封安瓿瓶(890898P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Still not finding the right product?
Explore all of our products under DOTMA
存储类别
11 - Combustible Solids
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 890898P-200MG | 04061835188581 |
| 890898P-25MG | 04061835188598 |